7000 Shoreline Court, Suite 201
South San Francisco
About Tricida, Inc.
Tricida, Inc. is a privately-held, late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). We are led by a management team with an accomplished and proven track record in discovering, developing, and commercializing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. The company is backed by world-class venture capital firms. We are expanding our existing group of exceptionally talented and well-motivated colleagues to develop and commercialize our first-in-class drug candidate, TRC101.
We recently completed enrollment in a pivotal Phase 3 clinical trial (TRCA-301) of TRC101 for the chronic treatment of metabolic acidosis. The TRCA-301 trial was designed to serve as the basis for the submission of a U.S. New Drug Application for TRC101. The application will be submitted under the Accelerated Approval Program, which was created by the U.S. Food and Drug Administration (FDA) to provide a mechanism for earlier approval based on a surrogate endpoint for drugs that treat serious conditions and fill an unmet medical need.
Tricida represents the best of both worlds – offering the exciting intensity and dynamics of a rapidly growing “older” startup, but with the financial resources of a larger organization! We need you to round out our team of exceptionally talented and motivated colleagues striving to make a big impact! Tricida’s shared culture of teamwork, camaraderie and empowerment is evident in the drive and focus our employees demonstrate, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD.
Competitive Compensation and Benefits include: Medical, Dental, and Vision Coverages, Life, AD&D, Disability, 401(k), Flexible Spending Plan, and Pre-IPO stock options. 15 vacation days per year and 11 paid holidays per year, which includes 1 floating holiday. Numerous employee perks.
46 articles with Tricida, Inc.
Tricida Announces Positive Topline Phase I/II Clinical Trial Results For TRC101 In 135 Subjects With Chronic Kidney Disease And Metabolic Acidosis
Tricida Announces FDA Acceptance Of Investigational New Drug Application For Lead Candidate TRC101 And Hiring Of Claire Lockey As Chief Development Officer And Edward J. Hejlek As General Counsel